• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Seeking a Revolution in Clinical Care Through AI

    Diversifying Supply Chains: New Opportunities Post Pandemic and After Brexit

    Addition by Subtraction: The Latest of Machining for Medtech

    Innovation Incubators: An R&D Roundtable

    Virtual Allies: Electronics Manufacturing Services Providers Offer Real Solutions
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Top News
    January AI Raises $8.8 Million in New Funding

    FDA Clears Ava Fertility Tracking Wearable Device

    First Patient in Europe Treated With Diamondback 360 Coronary Orbital Atherectomy System

    Artificial Intelligence, Machine Learning Adoption in Healthcare to Grow Considerably

    Japan to Lead APAC Assisted Reproductive Technology Devices Market
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Seeking a Revolution in Clinical Care Through AI

    Diversifying Supply Chains: New Opportunities Post Pandemic and After Brexit

    Addition by Subtraction: The Latest of Machining for Medtech

    Innovation Incubators: An R&D Roundtable

    Virtual Allies: Electronics Manufacturing Services Providers Offer Real Solutions
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Rethink Your Medtech ASC Strategy, Part 1

    Pandemic-Level Playing Field: How COVID-19 Made Space for Progress

    Tips for Reigniting Your MDR/IVDR Preparation

    Three Major Innovation Opportunities for Biomedical Textiles

    Use Vertical Integration to Increase Productivity, Drive Innovation
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    maxon

    K-Tube Technologies

    FUTEK Advanced Sensor Technology Inc.

    PTI Engineered Plastics Inc.

    Concise Engineering
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Refurbished Medical Equipment Testing and Certification Under the NEC

    Taking the First Step with Metal Components

    4 Trends Driving Medical Manufacturing in 2021

    Pioneering AI Solutions to Reinforce Healthcare Services

    The 8 Major Types of PPE Supply Chain Fraud
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Spectrum Plastics Group

    PTI Engineered Plastics Inc.

    maxon

    FUTEK Advanced Sensor Technology Inc.

    Medbio LLC
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • Podcasts
    • Resources
    • eBook
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Top30

    6. BD

    ...

    Related CONTENT
    • Abbott Recalls Ellipse ICDs
    • The 2019 Top 30 Global Medical Device Companies
    • The 2019 Top 30 Global Medical Device Companies
    • 2. Johnson & Johnson
    • 22. Dentsply Sirona
    07.30.19
    AT A GLANCE
    Rank: #6 (Last year: #9)
    $15.98 Billion
    Prior Fiscal: $12.10 Billion
    Percentage Change: +32.1%
    No. of Employees: 76,032
    Global Headquarters: Franklin Lakes, N.J.

    KEY EXECUTIVES
    Vincent A. Forlenza, Chairman and CEO
    Christopher R. Reidy, Exec. VP, CFO, and Chief Administrative Officer
    Thomas E. Polen, President and COO
    John A. DeFord, Exec. VP, Chief Technology Officer, Research and Development
    William R. Sigmund, Exec. VP and Chief Medical Officer
    Simon D. Campion, Exec. VP and President, Interventional Segment
    Patrick K. Kaltenbach, Exec. VP and President, Life Sciences Segment
    Alberto Mas, Exec. VP and President, Medical Segment

    Perhaps the most exciting medtech M&A news last year was that there wasn’t any. The industry had recently grown accustomed to nearly annual blockbuster deals—Zimmer and Biomet merged in 2014, with Medtronic and Covidien close on their heels; Abbott and St. Jude married in 2016; and right in MPO’s backyard, Becton, Dickinson and Company (BD) and C.R. Bard (Bard) formed their union in 2017. Although there were several small- to mid-sized deals keeping analysts’ interest up last year, they all lacked the gravity of the megamergers of recent years that were fast becoming a trend.

    “…we are now seeing a new class of what I like to call ‘Super OEMs’—Medtronic, Abbott, and now BD. That’s a list that will continue to grow,” Mark Bonifacio, founder and president of Bonifacio Consulting Services, told MPO when the BD-Bard deal was announced.

    Though significant, the $24 billion deal was considered “more of the same” in terms of medical device M&A. But whether the string of megamergers is healthy for the industry remains to be seen. Consolidation in this way can certainly help patients because of the clinical and procedural synergies created when joining complementary product portfolios. BD reaps the benefits of greater hospital buying group penetration with strong, high-margin products—particularly in urology and oncology, where it had lacked in market share. Combining two major companies also streamlines the supply chain as the merged companies look to consolidate supply base spending, which can be beneficial for product safety and eases the regulatory burden. However…

    “As good as it is for BD (and Bard shareholders), I question how good this is becoming for the industry,” Covington Associates VP Perry De Fazio told MPO. “It is easy to foresee a day with a ‘Big Three’ in each of the major clinical sectors (e.g., orthopedics, cardiovascular, neurology, etc.) with a couple of others sprinkled here and there. The ‘too big to fail’ problems we saw in the financial, automotive, and insurance industries (and still do, to an extent) may soon befall the medical device sector.”

    The worry is not without merit, as medical device industry trends typically lag a few years behind other industries. And it’s not just the greater economic system in danger—lifesaving technologies and treatments may also become more complicated to access should a “super OEM” crumble. 

    Thankfully, there appears to be no danger of that happening to BD—at least, not anytime soon. Thanks to Bard’s full integration, the firm’s sales nearly touched $16 billion last year, rising a monumental 32.1 percent from the year prior. A 24.5 percent gain was attributed to Bard, with the remaining growth covered by volume increase and favorable foreign currency transactions.

    As a result of Bard’s full integration, BD’s business structure was reorganized into three segments: Interventional, Medical, and Life Sciences. Last April, former Life Sciences president Alberto Mas was appointed as Medical Segment president, and former Agilent senior VP Patrick Kaltenbach was named to fill Mas’ spot. Bard’s former Surgery business president Simon Campion became the Interventional Segment’s president last August.

    The newly formed Interventional segment, which consists primarily of portfolios gained from Bard, posted $3 billion last year. Last year, surgery products brought in $1.2 billion, peripheral intervention solutions earned $1 billion, and urology and critical care offerings provided $800 million.


    ANALYST INSIGHTS: With the CareFusion and Bard acquisitions behind it, as well as the divestiture of the CareFusion respiratory division (now Vyaire) to Apax Partners, BD is poised for its next move. As the top 10 medical device companies grow even larger and the healthcare landscape continues to change at a rapid pace, BD looks to remain as part of the medtech giants.

    —Mark Bonifacio, Founder and President, Bonifacio Consulting Services



    BD acquired Austin, Texas-based TVA Medical for an undisclosed sum last July. TVA Medical, which develops minimally invasive vascular access products for chronic kidney disease patients needing hemodialysis, won de novo clearance for its everlinQ endoAVF hemodialysis device just two weeks before the deal closed. The device uses a pair of thin, flexible magnetic catheters inserted into the ulnar vein and artery through a small puncture. An electrode from the venous catheter then delivers radiofrequency energy to the artery and vein’s connection to create an arteriovenous fistula, allowing hemodialysis access without open surgery. BD changed the device’s name to WavelinQ EndoAVF upon TVA’s integration into its peripheral intervention business.

    The Medical franchise garnered $8.6 billion last year, rising 16.1 percent from the previous year. Medication delivery products (which posted $3.6 billion in sales last year, blossoming 29.6 percent) acquired from Bard were the main driver of the increase. Other underlying revenue growth arose from robust vascular access and vascular care sales, more dispensing and infusion system installations, prefillable syringe sales, and revenue from pen needles for diabetes.

    BD completed the sale of its remaining stake in its respiratory solutions joint venture Vyaire Medical to joint partner Apax Partners to the tune of $435 million last April. BD and Apax formed Vyaire Medical in 2016 around BD’s respiratory diagnostics, vital signs, and AirLife businesses. Upon closing, Vyaire became an independent company, establishing itself as “the leading pure-play medical device company in the respiratory space,” according to an Apax press statement.

    Medication management solutions gathered $2.5 billion of revenue last year, swelling 7.7 percent from 2017. The company launched new software to help identify drug diversion—a critical component of the opioid epidemic—at last November’s American Society of Health-System Pharmacists Midyear Meeting. The latest in the BD HealthSight platform for enterprise-wide medication management, the BD HealthSight diversion management application leverages data from the BD Pyxis ES system and electronic medical records to gather actionable insights for diversion investigations.

    The diabetes care and pharmaceutical systems franchises respectively achieved sales of $1.1 billion and $1.4 billion, growing 4.6 and 11.2 percent.

    The Life Sciences segment accrued $4.3 billion of proceeds last year, rising 8.6 percent. All three organizational units contributed to the gain. Improved sales of core microbiology products and the BD MAX molecular platform, research reagents and instruments, and a more severe influenza outbreak last year also padded this segment’s growth.

    BD sold its Advanced Bioprocessing business to Thermo Fisher Scientific for $477 million last October. With revenue of about $100 million, the business includes a strong technical services program with a variety of peptones to enhance cell culture media formulations, which improve yield and reduce variability in biopharmaceutical applications.

    Preanalytical systems posted a 5.5 percent revenue increase with $1.6 billion, but an FDA warning letter issued last January concerning modified BD Vacutainer blood collection tubes somewhat derailed sales. The letter cited that BD had marketed these tubes without proper clearance or approval and failed to submit medical device reports within the required timeframe. The violations were discovered through a July 2017 inspection of BD’s N.J. facility.

    The inspection also revealed the company had not evaluated or investigated a complaint regarding inaccurate blood lead test results when the modified tubes were used with Magellan Diagnostics’ LeadCare test systems. The maligned modification concerned specific Vacutainer tubes’ rubber stoppers. As BD came to discover, Magellan LeadCare testing systems’ Anodic Stripping Voltammetry (ASV) technology is not compatible with thiuram, which is found in the aforementioned rubber stoppers. Last March, BD advised clinicians not to use BD Vacutainer EDTA Lavender, Pink, and Tan top tubes and BD Vacutainer Lithium Heparin Green top tubes when using assays employing the ASV methodology.


    ANALYST INSIGHTS: Since its recent acquisition of Bard, BD seems to be highly internally focused to ensure its business units are focused on profitability to pay for the acquisition. While it’s unlikely BD will make major M&A deals in the near future, watch for the possibility of smaller, incremental deals to bolster its product lines.

    —Dave Sheppard, Co-Founder and Managing Director, MedWorld Advisors



    The PAXgene Blood ccfDNA (circulating cell-free DNA) tube launched in Europe last February. Developed by PreAnalytiX GmbH, a joint BD-QIAGEN venture, the plastic blood collection tube for ccfDNA molecular diagnostic testing applications (for example, cancer and non-invasive prenatal tests) includes a sample stabilization additive and BD Vacutainer Hemoguard technology to protect healthcare worker safety. Clinical labs can use it to stabilize samples when a sample cannot be processed on the same day it was collected.

    Diagnostics systems proceeds amounted to $1.5 billion last year, growing 11.5 percent. This area experienced more new product launch, approval, and clearance activity than any other franchise.

    Last January saw CE mark clearance shared with Check-Points Health B.V. for the BD MAX Check-Points CPO assay, a molecular screening test for antibiotic-resistant CPOs (carbapenemase-producing organisms, which are resistant to carbapenem, an antibiotic used to treat severe or high-risk bacterial infections). The assay can detect the five most common carbapenemase genes in under 2.5 hours. The Check-Points CPO assay replaced an earlier version of the test from Check-Points.

    The BD Onclarity HPV (human papillomavirus) assay obtained FDA approval last February. The test detects 14 types of high-risk HPV from specimens collected in a Pap test in a liquid-based cytology vial. The assay also identifies HPV genotypes associated with cervical cancers. Onclarity HPV is used as a primary screening test to triage patients with abnormal Pap test results, or can be used in conjunction with a Pap test. The test is run on the BD Viper LT benchtop molecular platform.

    The company unveiled a suite of diagnostic informatics and automation innovations at last April’s European Congress of Clinical Microbiology and Infectious Diseases. The new informatics and automation solutions for clinical laboratories included:
    • The BD Synapsys microbiology informatics solution for secure connectivity across instruments and locations
    • The BD COR high-throughput molecular platform, which supports assays for women’s health, STIs, and GI applications
    • BD Kiestra ID/AST modules that automate processing steps for bacterial identification and antibiotic susceptibility testing
    Last October the firm introduced the BD MAX MDR-TB panel in Europe. The single PCR-based molecular test simultaneously detects tuberculosis-causing bacteria and determines that bacteria’s resistance to isoniazid and rifampicin, two first-line drugs. By adding the MDR-TB panel to BD’s BACTEC MGIT products, European clinicians can now test TB and multidrug resistance as a first line test, then provide broader drug susceptibility testing and patient monitoring.

    The FDA cleared the BD Phoenix CPO detect test a month later. The test helps hospitals identify CPO infections in under 36 hours to implement infection control procedures, begin appropriate antibiotic therapies, and contain the spread of antimicrobial resistance. The CPO detect test is available in two configurations as part of the BD Phoenix automated microbiology system and is included on BD’s gram-negative panels.

    The BD MAX enteric viral panel, a molecular test to detect viral gastroenteritis pathogens, acquired FDA clearance last December. The nod completed BD’s suite of molecular tests for GI infection, which now includes enteric panels for intestinal bacterial, viral, and parasitic infections. The BD MAX enteric viral panel returns results for norovirus, adenovirus, human astrovirus, and sapovirus infections in less than 3.5 hours.

    The biosciences business grew 9 percent last year, earning $1.2 billion.

    The BD FACSymphony S6 cell sorter hit the market last April. The new platform leverages the FACSymphony cell analyzer to sort cell populations and better understand cell phenotypes for immunology and multi-omics research. The S6 instrument offers six-way sorting and can support analysis up to 30 parameters, and its ultra-quiet electronics system was adapted from the defense industry.

    BD made two notable investments in U.S. operations last year as well. About $150 million was invested last June in its existing Sumter, S.C., blood collection device manufacturing facility to create 125 jobs over the next few years. Last October, the firm also invested $200 million in its Nebraska facilities to create 300 jobs statewide. Over the last two years alone, BD has invested over $340 million in its Nebraska operations.
    Related Searches
    • neurology
    • president
    • test
    • non-invasive
    Suggested For You
    Abbott Recalls Ellipse ICDs Abbott Recalls Ellipse ICDs
    The 2019 Top 30 Global Medical Device Companies The 2019 Top 30 Global Medical Device Companies
    The 2019 Top 30 Global Medical Device Companies The 2019 Top 30 Global Medical Device Companies
    2. Johnson & Johnson 2. Johnson & Johnson
    22. Dentsply Sirona 22. Dentsply Sirona
    23. Canon Medical Systems 23. Canon Medical Systems
    24. Edwards Lifesciences 24. Edwards Lifesciences
    27. Hologic 27. Hologic
    29. Hillrom 29. Hillrom
    Hydromer Expands its Operational Executive Team With Two New Leaders Hydromer Expands its Operational Executive Team With Two New Leaders
    BD Offers Update on Infusion Pump Recall BD Offers Update on Infusion Pump Recall
    FDA OKs Abbott FDA OKs Abbott's Next-Gen MitraClip
    FDA Approves Abbott FDA Approves Abbott's Alinity s System
    BD Recalls SmartSite Syringe Administration Set Due to Risk of Leaks BD Recalls SmartSite Syringe Administration Set Due to Risk of Leaks
    Abbott & NIH Team Up to Advance Neuroscience Research Abbott & NIH Team Up to Advance Neuroscience Research

    Related Top30

    • The 2020 Top 30 Global Medical Device Companies

      The 2020 Top 30 Global Medical Device Companies

      Leadership changes, divestments, and portfolio-building partnerships—through acquisition or collaboration—were common threads among medtech’s largest players.
      MPO Editors 07.21.20

    • The 2019 Top 30 Global Medical Device Companies

      The 2019 Top 30 Global Medical Device Companies

      ...
      Sean Fenske, Michael Barbella, & Sam Brusco, MPO Editorial Staff 07.30.19

    • 1. Medtronic

      1. Medtronic

      ...
      07.30.19


    • 2. Johnson & Johnson

      2. Johnson & Johnson

      ...
      07.30.19

    • 3. GE Healthcare

      3. GE Healthcare

      ...
      07.30.19

    • 4. Abbott

      4. Abbott

      ...
      07.30.19


    • 5. Philips

      5. Philips

      ...
      07.30.19

    • 7. Cardinal Health

      7. Cardinal Health

      ...
      07.30.19

    • 7. Siemens Healthineers

      7. Siemens Healthineers

      ...
      07.30.19


    • 9. Stryker

      9. Stryker

      ...
      07.30.19

    • 10. Baxter

      10. Baxter

      ...
      07.30.19

    • 11. Boston Scientific

      11. Boston Scientific

      ...
      07.30.19


    • 12. Danaher

      12. Danaher

      ...
      07.30.19

    • 13. EssilorLuxottica

      13. EssilorLuxottica

      ...
      07.30.19

    • 14. Zimmer Biomet

      14. Zimmer Biomet

      ...
      07.30.19


    Trending
    • Portable, Home-Use Device Quickly Measures Inflammation Levels
    • Hardy Diagnostics Releases Rapid Test For COVID-19
    • 5 Ways Plastics Revolutionized The Healthcare Industry
    • FDA Breakthrough Device Designation Given To MI Transcatheter Heart Pump
    • Refurbished Medical Equipment Testing And Certification Under The NEC
    Breaking News
    • January AI Raises $8.8 Million in New Funding
    • FDA Clears Ava Fertility Tracking Wearable Device
    • First Patient in Europe Treated With Diamondback 360 Coronary Orbital Atherectomy System
    • Artificial Intelligence, Machine Learning Adoption in Healthcare to Grow Considerably
    • Japan to Lead APAC Assisted Reproductive Technology Devices Market
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • Seeking a Revolution in Clinical Care Through AI
    • Diversifying Supply Chains: New Opportunities Post Pandemic and After Brexit
    • Addition by Subtraction: The Latest of Machining for Medtech
    • Innovation Incubators: An R&D Roundtable
    • Virtual Allies: Electronics Manufacturing Services Providers Offer Real Solutions
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Preliminary Study Links Markers of Impaired Bone Health to Vegan Diet
    Refined Grains Linked to Heart Attack Risk, Early Death
    Kappa Bioscience Extends Research Partnership For COVID-19 Research
    Coatings World

    Latest Breaking News From Coatings World

    Nippon Paint Marine Wins Korea Export Award
    Universal Display Corporation, PPG Expand Global Production of UniversalPHOLED Materials
    PPG Introduces Premium Iso-free Primer Surfacer, Catalyst
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    January AI Raises $8.8 Million in New Funding
    FDA Clears Ava Fertility Tracking Wearable Device
    First Patient in Europe Treated With Diamondback 360 Coronary Orbital Atherectomy System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Spark Therapeutics Appoints CTO
    Cryoport Launches ESG Program
    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Top Beauty Products of 2021, According to HelloGiggles
    Estée Lauder Taps Ana de Armas as Global Brand Ambassador
    Sephora Announces Significant Expansion
    Happi

    Latest Breaking News From Happi

    What You're Reading on Happi.com
    Cosmetic Chemical Sales To Post CAGR 5.8% To 2025
    ACI Urges Senate to Approve Regan as EPA Administrator
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Marshall & Bruce Adds Koenig & Bauer Rapida 106 41-Inch Seven-Color Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    FTA converts Forum & INFOFLEX to virtual events
    Xeikon launches two new digital label printing presses
    UFlex adds capacity in packaging films
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Texas Medical Technology Partners with My Protect Kit
    Mexico City Single-Use Plastics Ban Leads to Tampon Shortage
    Believe Diapers Launch in U.S.
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login